Anti-Diabetes Drugs - Botswana | Statista Market Forecast

The Anti-Diabetes Drugs market in Botswana is expected to witness a significant growth in revenue, with projections indicating that it will reach US$7.57m units by the year 2024.
Moreover, this market is anticipated to display a steady annual growth rate (CAGR 2024-2029) of 7.69%, ultimately resulting in a market volume of US$10.96m units by 2029.
In the global landscape, it is noteworthy that United States is projected to generate the highest revenue in this sector, amounting to US$37.84bn units by the year 2024.
Botswana's increasing prevalence of diabetes has led to a rising demand for innovative anti-diabetes drugs in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Botswana is experiencing significant growth in recent years.

Customer preferences: The demand for Anti-Diabetes Drugs in Botswana is growing due to the increasing prevalence of diabetes in the country. Diabetes is a chronic disease that affects a large percentage of the population in Botswana. As a result, there is a high demand for Anti-Diabetes Drugs to manage the disease. Patients in Botswana prefer drugs that are effective, affordable, and have minimal side effects.

Trends in the market: The Anti-Diabetes Drugs market in Botswana is dominated by multinational pharmaceutical companies. These companies offer a wide range of Anti-Diabetes Drugs that cater to the needs of patients in Botswana. The market is also witnessing the introduction of new drugs that are more effective in managing diabetes. These drugs are gaining popularity among patients due to their effectiveness and minimal side effects. The market is expected to continue growing in the coming years due to the increasing prevalence of diabetes in Botswana.

Local special circumstances: Botswana is a developing country with a growing economy. The government is investing heavily in healthcare infrastructure and services to improve the health of its citizens. The government has also implemented various initiatives to increase awareness about diabetes and its management. These initiatives have increased the demand for Anti-Diabetes Drugs in Botswana. Additionally, the government has made efforts to make Anti-Diabetes Drugs more affordable to patients. This has led to an increase in the accessibility of these drugs to patients in Botswana.

Underlying macroeconomic factors: Botswana's economy is heavily dependent on the mining sector, which accounts for a significant portion of the country's GDP. The country has a stable political environment, which has attracted foreign investment. The growing economy has led to an increase in the disposable income of the population, which has contributed to the growth of the Anti-Diabetes Drugs market. Additionally, the government's investment in healthcare infrastructure and services has also contributed to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.